Fig. 4

Clusters A–C subtypes correlate with predictors of immunotherapy efficacy. We predicted the difference in immunotherapy between the three clustering subgroups according to the immunophenotypic score (IPS): a IPS of CTLA4 alone effect for clusters A–C subtypes. b IPS of clusters A–C subtypes in CTLA4 and PD1 combination effect. Cluster C outperformed cluster A when CTLA4 was administered alone (P < 0.05), whereas clusters B and C showed no difference in treatment effects. The treatment effect of cluster C was better than that of cluster B following combined therapy with CTLA4 and PD1 (P < 0.001); clusters A and C showed no difference in treatment effects. c Differential expression of immune checkpoints in clusters A–C. Except for CTLA4 expression, which did not significantly differ among the three subgroups. The expression of all other immune checkpoints differed (HAVCR2, PDCD1LG2: P < 0.001; CD274, PDCD1, LAG3: P < 0.01; TIGIT, SIGLEC15: P < 0.05). The eight immune checkpoints showed the highest expression and immune scores in cluster A. *P < 0.05 and **P < 0.01, ***P < 0.001. *P < 0.05 and **P < 0.01, ***P < 0.001. IPS, immunophenotype score